Novel application of S-nitrosoglutathione-Sepharose to identify proteins that are potential targets for S-nitrosoglutathione-induced mixed-disulphide formation
In some embodiments, the otic formulation or composition comprises between about 0.01% to about 2% by weight of the viscosity modulating agent(s)
This high concentration is a testament to its absolute necessity for cellular survival, as it mirrors the cellular concentrations of essential nutrients like glucose, potassium, and cholesterol
This is one of its advantages as a stacking partner it adds metabolic benefits without introducing hormonal complexity or the need for post-cycle therapy
The peptide suppresses formation of pro-inflammatory mediators including TGF-1, creating an environment conducive to regeneration rather than chronic inflammation
Award amounts for NSF SBIR/STTR awards will be: Phase I: $305,000 over 6-18 months Phase II: $1,250,000 over 24 months Fast-Track: $1,555,000, with 6-12 months in Phase I and 18-24 months in Phase II NSF will accept Strategic Breakthrough Award proposals for Phase II awardees, upon recommendation by the cognizant Program Officer
